Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar 18;53(3):1900283.
doi: 10.1183/13993003.00283-2019. Print 2019 Mar.

Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies

Paul J Wolters  1 , Vincent Cottin  2
Affiliations
Free article
Editorial

Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies

Paul J Wolters et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P.J. Wolters reports grants and personal fees from Boehringer Ingelheim, grants from Medimmune and Genentech, and personal fees from Roche, Blade Therapeutics and Pliant, outside the submitted work. Conflict of interest: V. Cottin reports personal fees for lecturing and consultancy, and non-financial support (travel to medical meetings) from Actelion, grants, personal fees for lecturing and consultancy, and non-financial support (travel to medical meetings) from Boehringer Ingelheim and Roche, personal fees for consultancy from Bayer/MSD, personal fees for adjudication committee work from Gilead, personal fees for lecturing and consultancy from Novartis, grants from Sanofi, personal fees for data and safety monitoring board work from Promedior and Celgene, and personal fees for consultancy from Galapagos, outside the submitted work.

Comment on

  • Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
    Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M. Khalil N, et al. Eur Respir J. 2019 Mar 18;53(3):1800663. doi: 10.1183/13993003.00663-2018. Print 2019 Mar. Eur Respir J. 2019. PMID: 30578394 Free PMC article. Clinical Trial.
  • A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.
    Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM. Lukey PT, et al. Eur Respir J. 2019 Mar 18;53(3):1801992. doi: 10.1183/13993003.01992-2018. Print 2019 Mar. Eur Respir J. 2019. PMID: 30765508 Clinical Trial.

LinkOut - more resources